These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 30832701

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
    Richard KR, Shelburne JS, Kirk JK.
    Clin Ther; 2011 Nov; 33(11):1609-29. PubMed ID: 22071236
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
    Kaneko M, Narukawa M.
    Diabetes Res Clin Pract; 2016 Jun; 116():171-82. PubMed ID: 27321333
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effect of dipeptidyl peptidase-4 inhibitors on tumor necrosis factor alpha levels in patients with type 2 diabetes mellitus.
    Zhao L, Meng J, Bai X, Zhang D, Yang X, Yang Y, Cai G, Liu X.
    Eur J Med Res; 2024 Jul 12; 29(1):363. PubMed ID: 38997754
    [Abstract] [Full Text] [Related]

  • 29. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.
    Scheen AJ.
    Diabetes Metab; 2018 Nov 12; 44(5):386-392. PubMed ID: 30126735
    [Abstract] [Full Text] [Related]

  • 30. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K, Gräber S.
    Diabetes Obes Metab; 2012 Dec 12; 14(12):1061-72. PubMed ID: 22519906
    [Abstract] [Full Text] [Related]

  • 31. Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials.
    Li R, Wang R, Li H, Sun S, Zou M, Cheng G.
    Diabetes Metab Res Rev; 2016 Sep 12; 32(6):460-9. PubMed ID: 26433213
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors.
    Ryan G.
    Postgrad Med; 2015 Sep 12; 127(8):842-54. PubMed ID: 26436470
    [Abstract] [Full Text] [Related]

  • 39. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E, Cigolini M.
    Nutr Metab Cardiovasc Dis; 2016 Apr 12; 26(4):273-84. PubMed ID: 27038847
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.